In remarks to a Council of the Americas conference, Tai said the world had made real strides toward ending the pandemic but that a lot of work lies ahead.
“That includes making the vaccine widely available and addressing the global inequity in vaccine access,” she said. “This is not just a public health requirement. Our economic recovery depends on it.”
Tai is due to discuss demands from developing countries for a World Trade Organization waiver of intellectual property rights on coronavirus vaccines during a WTO General Council meeting later this week.
She has been meeting with the chief executives of the major vaccine manufacturers in recent days to discuss the waiver proposal and ways to boost vaccine production and distribution.
White House Chief of Staff Ron Klain said on Sunday, May 2, that Tai would “start talks on how we can get this vaccine more widely distributed, more widely licensed, more widely shared,” adding that more details would be offered in coming days.
A majority of Democrats in the US House of Representatives, and many liberal Democratic senators have urged President Joe Biden’s administration to support the vaccine intellectual property waiver, arguing it would help save lives and prioritize people over drug company profits.
The pharmaceuticals industry sees the proposed waiver as too broad and would set a precedent that would erode incentives to develop future vaccines.
Democratic Representative Earl Blumenauer, head of the Ways and Means trade subcommittee, told reporters that Tai and other US officials were trying to develop a path forward, and narrowing the scope of the proposed waiver could help reassure industry.
Representative Rosa DeLauro told reporters she spoke with Commerce Secretary Gina Raimondo earlier on April 28 and saw “some positive signs” the Biden administration was committed to aiding other countries in the current humanitarian crisis.
A dozen House of Representatives Republicans wrote to Tai on Tuesday to urge her to continue to oppose the IP rights waiver, arguing it would not meaningfully improve vaccine availability.
“The scope of the requested waiver is overbroad and unjustified in light of the economic harm it would cause and the negligible benefits it would provide,” wrote the members, led by House Judiciary Committee senior Republican Darrell Issa. – Rappler.com